The report reiterates a BUY rating with a revised target price of INR500, citing a steady quarter with healthy NII growth, improving asset quality, and robust RoA outlook of 2.0-2.1%.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
All houses
HDFC Securities
Motilal Oswal
Tata Asset Management
Mirae Asset Sharekhan
India IPO
Jainam
GEPL Capital
Way2Wealth
SBICAP Securities
Angel One
Axis Securities
ICICI Direct Research Retail
Religare
Arete Securities
Formerly known as Way2Wealth
ICICI Direct
Way2Wealth Securities
ICICI Securities
quant Mutual Fund
Kotak Securities
JM Financial
ICICI Securities – Retail
Global Markets by Vested
Ventura Securities
Prabhudas Lilladher
Industrial Asphalts
ITC Hotels
Exterminators PLC
Emkay Global
Private Client Group Research summarized from KIE research report
Kahawatte Plantations PLC
Elara Securities
258 notes from Motilal Oswal · 01 Oct 2026, 00:00 to 01 Nov 2026, 00:00 IST
The report reiterates a BUY rating on Coforge with a target price of INR2,370 (25% upside), citing strong order intake, margin guidance upgrade to 16% for FY27, and expected growth acceleration in 2HFY27 as Encora integration completes.
Read this note →The report reiterates a BUY rating on Infosys with a target price of INR1,300 (13% upside), despite noting a miss on 2QFY27 revenue, a cut in FY27 revenue growth guidance to 1-2% YoY CC from 1.5-3.0%, and margin pressure from competitive pricing and the Daimler deal exit.
Read this note →The report's quant intraday strategy lists Vodafone Idea (IDEA) as a sell idea for the day's session.
Read this note →The report's quant intraday strategy lists Coal India as a sell idea for the day's session.
Read this note →The report flags a technical SELL idea on Jubilant Foodworks futures citing a range breakdown and bearish candle.
Read this note →The report flags a technical SELL idea on Muthoot Finance futures citing continuation of a downtrend and trading below the 20 DEMA.
Read this note →The report gives a technical conviction BUY idea on HCL Technologies at CMP ₹1,424 with a target of ₹1,512 and stop loss ₹1,380, citing an inverted head and shoulder breakout.
Read this note →The report lists Adani Ports as a Focus Investment Idea with a Buy rating and 22% upside over a 1-year horizon.
Read this note →The report lists Lenskart as a Focus Investment Idea with a Buy rating and 27% upside over a 1-year horizon.
Read this note →The report lists Molbio Diagnostics as a Focus Investment Idea with a Buy rating and 36% upside over a 1-year horizon.
Read this note →The report lists Syrma SGS Tech as a Focus Investment Idea with a Buy rating and 37% upside over a 1-year horizon.
Read this note →The report includes Sona BLW Precision as a 20% weighted constituent of its EV Value Chain basket idea.
Read this note →The report includes Ather Energy as a 20% weighted constituent of its EV Value Chain basket idea.
Read this note →The report includes Uno Minda as a 20% weighted constituent of its EV Value Chain basket idea.
Read this note →The report includes TVS Motors as a 20% weighted constituent of its EV Value Chain basket idea.
Read this note →The report includes Bajaj Auto as a 20% weighted constituent of its EV Value Chain basket idea.
Read this note →The report cites peptide API demand growth from oral Wegovy and favorable US tariff treatment as supporting a BUY call on Divi's Labs with 14% upside and a stop loss at ₹8,870.
Read this note →The report highlights Emcure's domestic formulations growth of 19.3% YoY outperforming the IPM and assigns a BUY rating with 33% upside to target.
Read this note →The report states Indian Hotels posted 22% YoY revenue growth in 2QFY27, raised FY27 revenue guidance to 15-17%, and assigns a BUY rating with 16% upside to target.
Read this note →The report states Persistent Systems launched a QIP to raise up to US$450 million at a floor price of ₹5,550 per share.
Read this note →The report notes SRF's 2QFY27 revenue of ₹49.0 billion rose ~35% YoY but EBITDA missed estimates due to a 150bp YoY margin contraction to 20.6%.
Read this note →The report states KEI's 2QFY27 revenue of ₹37.8 billion grew 39% YoY and beat estimates by 9%, led by the C&W segment.
Read this note →The report notes Zydus received final USFDA approval for a generic estradiol/levonorgestrel hormone patch addressing a ~US$45.7 million US market.
Read this note →The report states BEL secured additional orders worth ₹1,011 crore since October 13 across radar, communication and defence equipment segments.
Read this note →